CASI announced on 29 September 2020 that it had adjusted its licence and marketing agreement with Juventas, the developer of the CAR-T therapy CNCT19. Under the new agreement, the two companies will co-market the product and have a profit-sharing agreement, as opposed to the previous model in which CASI would have owed milestones and royalties (all undisclosed). The new agreement should make Juventas more viable as a standalone entity, capable of raising independent capital to support its intern ....
01 Oct 2020
CASI Pharmaceuticals - CASI restructures CAR-T deal
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - CASI restructures CAR-T deal
CASI Pharmaceuticals, Inc. (CASI:NAS) | 0 0 0.0%
- Published:
01 Oct 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
6
CASI announced on 29 September 2020 that it had adjusted its licence and marketing agreement with Juventas, the developer of the CAR-T therapy CNCT19. Under the new agreement, the two companies will co-market the product and have a profit-sharing agreement, as opposed to the previous model in which CASI would have owed milestones and royalties (all undisclosed). The new agreement should make Juventas more viable as a standalone entity, capable of raising independent capital to support its intern ....